Home / Health / New IVF Tech Promises Less Pain, More Hope
New IVF Tech Promises Less Pain, More Hope
1 Jan
Summary
- Gameto's therapy bypasses painful daily hormone injections for IVF.
- Living cells mimic ovarian cells to mature eggs in a lab.
- Potential implications extend beyond fertility to aging conditions.
Gameto, a six-year-old company, is on the verge of a significant innovation in IVF treatment. Their new therapy, Fertilo, requires only one or two injections to retrieve immature eggs, bypassing the arduous two-week course of daily hormone shots typically associated with IVF. This approach uses living cells in a lab to mature the eggs, offering a less physically and emotionally taxing experience for patients.
The technology builds on Nobel Prize-winning research into induced pluripotent stem cells (iPSC). Beyond fertility, Gameto suggests its method of replacing unhealthy ovarian cells with lab-made ones could combat aging-related conditions like cardiovascular disease and osteoporosis. In the past year, Fertilo has been cleared for use in a dozen countries, and 11 babies have been born through its application.
If approved by the U.S. FDA, Fertilo would mark the first IVF treatment realizing the Nobel discovery domestically and the first new IVF drug in the U.S. in over two decades. This innovation addresses a critical need in women's health, an area historically underfunded and under-researched, with potential to reshape fertility care and impact broader health challenges associated with ovarian aging.
